Study of AZD5305 when given in combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer

Trial Identifier: D9720C00003
Sponsor: AstraZeneca
Collaborator:
Bayer
Start Date: June 2022
Primary Completion Date: April 2031
Study Completion Date: April 2031
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Camperdown, AU, 2050
AU Darlinghurst, AU, 2010
AU East Melbourne, AU, 3002
AU Heidelberg, AU, 3084
AU Melbourne, AU, 3004
AU St Leonards, AU, 2065
GB Cambridge, GB, CB2 0QQ
GB Glasgow, GB, G12 0YN
GB Manchester, GB, M20 4BX
GB Plymouth, GB, PL6 8DH
IT Candiolo, IT, 10060
IT Milano, IT, 20133
IT Orbassano, IT, 10043
IT Padova, IT, 35128
US, MI Detroit, MI, US, 48202
US, MI Detroit, MI, US, 48201
US, NY Syracuse, NY, US, 13210
US, SC Myrtle Beach, SC, US, 29572
US, Texas Houston, Texas, US, 77030
US, TX Houston, TX, US, 77094